Back

High fibrinogen-to-albumin ratio with type 2 diabetes mellitus is associated with poor prognosis in patients undergoing percutaneous coronary intervention: 5-year findings from a large cohort

7 April 2022 (09:30 - 14:00)
Organised by:
Congress Presentation Part of: Rapid fire abstracts session 1 - Secondary Prevention and Rehabilitation Percutaneous Coronary Intervention (PCI) EAPC Premium Access ESC Preventive Cardiology 2022

About the speaker

Photo
Doctor Peizhi Wang

Peking Union Medical College Hospital, Beijing (China)

4 More presentations in this session

Presentation thumbnail
Ventricular-arterial coupling derived from proximal aortic stiffness: impact on aerobic capacity across the heart failure spectrum.
Doctor N. Pugliese (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
SGLT2 inhibitors in heart failure with preserved and reduced ejection fraction: a systematic review and meta-analysis
Doctor V. Tsampasian (Norwich, GB)
Abstract Slides Video
Presentation thumbnail
Insomnia was associated with increased risk of recurrent cardiovascular events in coronary heart disease patients
Mr L. Frojd (Drammen, NO)
Abstract Slides Video
Presentation thumbnail
Effects of once-weekly semaglutide on coronary outcomes in patients with type 2 diabetes mellitus with or at high risk for cardiovascular disease: insights from the SUSTAIN-6 trial
Doctor A. Kolkailah (Dallas, US)
Abstract Slides Video

Access the full session

Session thumbnail
Rapid fire abstracts session 1 - Secondary Prevention and Rehabilitation

The Event

Event poster

ESC Preventive Cardiology 2022

7 April - 9 April 2022
You may be interested in
thumbnail
Congress Presentation
Percutaneous intervention is better than surgery in real life for most patients: pro
thumbnail
Congress Presentation
Association of PCI with outcomes in stable coronary artery disease
thumbnail
Congress Presentation
Prognostic impact of intravascular imaging in percutaneous coronary intervention according to atherothrombotic risk

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources